Review Article
Ozone in Dermatology – Between Science and Therapy
Valentina Broshtilova,
Ivan Vasilevski,
Yoanna Velevska,
Irina Yungareva,
Alexander Trenovski,
Yoanna Petkova,
Sonya Marina*
Issue:
Volume 9, Issue 1, June 2026
Pages:
1-9
Received:
27 November 2025
Accepted:
10 December 2025
Published:
26 January 2026
Abstract: Ozone therapy is increasingly utilized in dermatology owing to its multimodal antimicrobial, anti-inflammatory, antioxidant, and regenerative properties; however, its clinical implementation remains heterogeneous and the quality of supporting evidence varies across indications. This review critically evaluates the mechanisms of action, clinical applications, safety profile, and future perspectives of ozone therapy in dermatological practice. A structured literature search of PubMed, Scopus, and Web of Science covering the period from January 2000 to December 2024 identified 60 eligible human studies, which were assessed according to study design and methodological quality. Biologically, ozone exerts its effects through controlled oxidative stimulation, leading to activation of the Nrf2/EpRE pathway, improvement of microcirculation, and promotion of immunomodulation, tissue oxygenation, and wound healing. Moderate-quality evidence supports the use of ozone as an adjunctive treatment for chronic ulcers and burns (evidence level B), while limited to moderate evidence suggests potential benefits in acne, atopic and seborrheic dermatitis, cutaneous infections, and psoriasis (evidence levels C–D). Aesthetic and regenerative applications remain largely experimental (evidence level D). When administered by trained professionals using appropriate protocols, ozone therapy demonstrates a generally favorable safety profile, with adverse events being infrequent and typically mild. Overall, ozone therapy shows meaningful therapeutic potential as an adjunctive modality in dermatology, particularly for chronic and treatment-resistant dermatoses; nevertheless, broader adoption will require standardized dosing and delivery protocols, high-quality randomized clinical trials, and robust long-term safety data, supported by continued technological advances and molecular research to enable more targeted, evidence-based integration into clinical practice.
Abstract: Ozone therapy is increasingly utilized in dermatology owing to its multimodal antimicrobial, anti-inflammatory, antioxidant, and regenerative properties; however, its clinical implementation remains heterogeneous and the quality of supporting evidence varies across indications. This review critically evaluates the mechanisms of action, clinical app...
Show More
Research Article
Clinico-epidemiological and Therapeutic Aspects of Alopecia Areata in Children at the Dermatology Department, University Hospital of Antananarivo, Madagascar
Herin'Ny Fitiavana Princia Andriatahina*
,
Andrianandrianina Mbolatiana Kiady Armando Rakotomanana,
Fandresena Arilala Sendrasoa,
Tsiory Iarintsoa Razafimaharo,
Moril Sata,
Fenohasina Rakotonandrasana,
Onivola Raharolahy,
Malalaniaina Andrianarison,
Irina Mamisoa Ranaivo,
Lala Soavina Ramarozatovo,
Fahafahantsoa Rabenja Rapelanoro
Issue:
Volume 9, Issue 1, June 2026
Pages:
10-16
Received:
13 January 2026
Accepted:
26 January 2026
Published:
9 February 2026
DOI:
10.11648/j.ijcd.20260901.12
Downloads:
Views:
Abstract: Introduction: Alopecia areata (AA) is an autoimmune disease of the hair follicles that causes non-scarring hair loss. We aim to describe the epidemiological, clinical, and therapeutic aspects of AA seen in Malagasy children. Materials and Methods: A descriptive retrospective study was conducted over a 71-month period in children <15 years old with AA, seen in the two dermatology departments of the University Hospital Joseph Raseta Befelatanana, Antananarivo Madagascar. Results: Twenty-five cases of AA in children were included. The sex ratio was 0.47. The mean age was 10.36 ± 3.7 years. Patchy alopecia was the most frequent presentation (n=12), then totalis alopecia (n=3), ophiasis alopecia (n=2), and finally alopecia universalis (n=1). An association of patchy and ophiasis alopecia was found in 7 cases. The first-line treatments used were very potent topical corticosteroids in 18 cases, combined with systemic treatment in 8 cases. Mini-pulse corticosteroid therapy was used in 10 cases. Corticosteroid boluses (5-10 mg/kg/day for 3 days) were used in 5 cases. As a second-line treatment, methotrexate (5-7.5 mg/week) was used in 3 cases. After first-line treatment, complete regrowth (≥80%) was observed in 3 patients, and partial regrowth (29 to 80%) in 14 patients. Conclusion: AA has a heterogeneous presentation and unpredictable clinical course. Our study shows the therapeutic difficulty of AA in children.
Abstract: Introduction: Alopecia areata (AA) is an autoimmune disease of the hair follicles that causes non-scarring hair loss. We aim to describe the epidemiological, clinical, and therapeutic aspects of AA seen in Malagasy children. Materials and Methods: A descriptive retrospective study was conducted over a 71-month period in children ...
Show More
